Last reviewed · How we verify
MMV390048 dose to be determined mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
MMV390048 dose to be determined mg (MMV390048 dose to be determined mg) — Medicines for Malaria Venture.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MMV390048 dose to be determined mg TARGET | MMV390048 dose to be determined mg | Medicines for Malaria Venture | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MMV390048 dose to be determined mg CI watch — RSS
- MMV390048 dose to be determined mg CI watch — Atom
- MMV390048 dose to be determined mg CI watch — JSON
- MMV390048 dose to be determined mg alone — RSS
Cite this brief
Drug Landscape (2026). MMV390048 dose to be determined mg — Competitive Intelligence Brief. https://druglandscape.com/ci/mmv390048-dose-to-be-determined-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab